ADGRE2-edited allogeneic hematopoietic stem cell therapy (Vor Bio)

N/A

Report date: 2025/06/11 10:53:38

Base Information

Drug NameADGRE2-edited allogeneic hematopoietic stem cell therapy (Vor Bio)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionAdhesion G protein-coupled receptor E2 modulators
TargetsAdhesion G protein-coupled receptor E2
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVor Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesVor Biopharma Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A